Cimzia® - Polyarticular Juvenile Idiopathic Arthritis

Cimzia® (certolizumab pegol) is a tumor necrosis factor (TNF) blocker indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.

 

Warning: serious infections and malignancy
See full prescribing information for complete boxed warning.

  • Increased risk of serious infections leading to hospitalisation or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1)
  • Cimzia should be discontinued if a patient develops a serious infection or sepsis (5.1)
  • Perform test for latent TB; if positive, start treatment for TB prior to starting Cimzia (5.1)
  • Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)
  • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Cimzia is a member (5.2).

Prescribing Information USA